Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
|Articles|April 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
- Volume 4
- Issue 4 Suppl
Pharmacoeconomics Perspectives: Payers, Providers, and Patients
Advertisement
Articles in this issue
over 28 years ago
Participating Facultyover 28 years ago
Coronary Heart Disease in the United Statesover 28 years ago
Mechanisms of Acute Coronary Eventsover 28 years ago
Primary Preventionover 28 years ago
Pravastatin Event Reduction Analysisover 28 years ago
Secondary Preventionover 28 years ago
Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?over 28 years ago
Methods and Mindsets in Pharmacoeconomicsover 28 years ago
Issues and Controversies in PharmacoeconomicsAdvertisement
Related to this article
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Who Recommends COVID-19 Vaccines Without ACIP?
5